MorphoSys AG operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares MorphoSys AG with three other
miscellaneous service companies in Europe:
Innate Pharma S.A.
sales of 56.16 million Euro [US$64.48 million]
of which 100%
was Licensing Revenue),
(51.01 million Euro [US$58.56 million]
of which 105%
was Therapeutics), and
based in the United Kingdom
(£39.23 million [US$51.22 million]
of which 67%
was Clinical Research Service).
During the year ended December of 2016, sales at
MorphoSys AG were 49.74 million Euro (US$57.11 million).
decrease of 53.2%
versus 2015, when the company's sales were 106.22 million Euro.
Contributing to the drop in overall sales was the 99.0% decline
in Proprietary Development, from 59.94 million Euro to 621,000.00 Euro.
However, these declines were partially offset by the increase in sales of
Partnered Discovery (up 6.1% to 49.12 million Euro)